Screener
CRISPR Therapeutics CRSP Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Research and development | 68,574 | 72,484 |
| General and administrative | 17,183 | 19,296 |
| Collaboration expense, net | 45,949 | 57,509 |
| Total operating expenses | 131,706 | 149,289 |
| Loss from operations | (130,248) | (148,424) |
| Other income: | ||
| Other income, net | 8,156 | 13,537 |
| Total other income, net | 8,156 | 13,537 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's total operating expenses?
- CRISPR Therapeutics (CRSP) reported total operating expenses of $131.71M in Q1 2026.
- How has CRISPR Therapeutics's total operating expenses changed year-over-year?
- CRISPR Therapeutics's total operating expenses decreased by 11.8% year-over-year, from $149.29M to $131.71M.
- What is the long-term trend for CRISPR Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's total operating expenses has grown at a 5.4% compound annual growth rate (CAGR), from $541.44M to $668.08M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about CRISPR Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude